Adsorbed Diphtheria Tetanus Combined Vaccine吸附白喉破伤风联合疫苗

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

破伤风类毒素原液加入氢氧化铝佐剂制成是一种在国家药监局注册认定的药品。标注生产企业为北京天坛生物制品股份有限公司。

该药品暂无关联的活性成分信息。

该药品标注的生产企业为:北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司、北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司、北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 吸附白喉破伤风联合疫苗) is a medicine registered with the national drug regulatory authority. It is manufactured by Chinese legal name: 北京天坛生物制品股份有限公司.

No active ingredient relationships are currently recorded for this product in MedicineGraph.

Manufacturers recorded for this product: 北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司, 北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司, 北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 吸附白喉破伤风联合疫苗Adsorbed Diphtheria Tetanus Combined Vaccine
  • 规格Specification: 每支2.0ml。每1次人用剂量0.5ml,含白喉类毒素效价应不低于30IU,破伤风类毒素效价应不低于40IU。Recorded Chinese description: 每支2.0ml。每1次人用剂量0.5ml,含白喉类毒素效价应不低于30IU,破伤风类毒素效价应不低于40IU。

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

生产企业Manufacturer

  • 北京天坛生物制品股份有限公司Chinese legal name: 北京天坛生物制品股份有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字S10820027

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字S10820027

Manufacturer

Chinese legal name: 北京天坛生物制品股份有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Storage

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字S10820027

生产企业

北京天坛生物制品股份有限公司(国产)

适应症

{接种对象}12岁以上人群。全年均适宜接种。|{作用与用途}接种本疫苗后,可使机体产生免疫应答反应用于经吸附百白破联合疫苗全程免疫后的儿童的白喉和破伤风加强免疫。|{免疫程序和剂量}(1)上臂三角肌肌内注射。(2)注射1次,注射剂量0.5ml。

不良反应

注射本品后局部可有红肿、疼痛、发痒,或有低热、疲倦、头痛等,一般不需处理即自行消退。局部可能有硬结,1~2个月即可吸收。

禁忌

尚不明确。

贮藏

于2~8℃避光保存和运输。

规格

每支2.0ml。每1次人用剂量0.5ml,含白喉类毒素效价应不低于30IU,破伤风类毒素效价应不低于40IU。

证据Evidence

  • 批准文号: 国药准字S10820027
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.